Featured Content

  • Sage Therapeutics: Hot IPO, Great Start in CNS Last week, we saw a very successful IPO for Sage Therapeutics (SAGE) - a company that focuses on treating rare diseases that affect the generic cialis next day shipping central nervous system. Although the cialis tablets company is still in the viagra alternative relatively early stages of the buy cialis professional development cycle, the company has already attained an enterprise valuation of $696 M after investors brought the buy cialis no prescription online stock 67% higher last Friday. 
  • Don’t Buy Into In Prana’s Data Mining Strategy Despite the cnadian viagra india continuing pain in the biotech sector, Prana (PRAN) is up 15% at time of writing based on a press release issued yesterday about the cialis us company’s efforts to revive the buy cialis online failed Alzheimer’s drug PBT2.  
  • Bigger Moves Coming For Exelixis It took a while for investor sentiment in Exelixis (EXEL) to recover after the pfizer viagra cheap company released less-than-stellar interim results for its Phase III Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial for cabozantinib (COMET-1) back in March, but it appears that positive news from the cobimetinib program is helping to lighten the mood a bit.
More News

Subscriber Only Content

More News

Sector News

More News


BioMedReports Puma Bio More Than $100 After-Hours On Trial PB272; CEL-SCI Receives Regulatory Clearance To Expand Phase III ... http://t.co/C4MJBrrwSo
6hreplyretweetfavorite
BioMedReports Study reveals nervous system's role in asthma attacks. http://t.co/2bx2IMgFF3
15hreplyretweetfavorite
BioMedReports Synta Announces Ganetespib Into Phase 3 Extension Of AML LI-1 Study; Ignyta Announces Phase I/II Clinical Tria... http://t.co/PPbxqFxMyi
navigation
Benzinga.com supporter Seeking Alpha Certified

RSS Subscription